Founded in 2010, Curis Lifesciences develops and manufactures a range of pharmaceutical formulations, including tablets, capsules, oral liquids, external preparations and sterile eye ointments. The company operates a state-of-the-art manufacturing plant in Sanand, Gujarat, and supplies both in India and abroad on a contract manufacturing and loan licensing basis. It serves more than 100 corporate clients across India and exports under its own brands to countries such as Yemen and Kenya.
Financially, Curis Lifesciences has reported consistent growth. Revenue rose 38% year-on-year to Rs 49.65 crore in FY25, while profit after tax (PAT) rose 25% to Rs 6.11 crore. The company’s EBITDA margin was 19.4% and PAT margin 12.4%, reflecting strong operational efficiency.
Proceeds from the IPO will be mainly used for upgrading and improving manufacturing facilities (Rs 2.44 crore), construction of new warehousing facility (Rs 3.62 crore), prepayment of secured loans (Rs 1.86 crore), product registrations in new markets (Rs 2.69 crore), working capital (Rs 11.25 crore) and general corporate purposes (Rs 2.85 crore).
In summary, the Curis Lifesciences IPO has seen strong investor participation, supported by healthy fundamentals and moderate valuations. While the GMP indicates a steady start, the company’s long-term success will depend on its ability to scale up its operations, maintain profitability and expand exports in a competitive market.
#Curis #Lifesciences #IPO #listed #today #Check #GMP #prior #debut